Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 12/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 12/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089733 | 0.88 | AKR1C3 (0.42) | AKR1C3AKR1C2PTGS1ALDH1A1EPHX2 | |
| SCHEMBL5096556 | 0.87 | AKR1C3 (0.59) | AKR1C3AKR1C2PTGS1TAS2R14PTGS2 | |
| SCHEMBL8292135 | 0.84 | SLC9A1 (0.57) | — | |
| SCHEMBL5089742 | 0.76 | AKR1C3 (0.48) | AKR1C3AKR1C2PTGS1TAS2R14PTGS2 | |
| SCHEMBL31046834 | 0.75 | WDR5 (0.40) | AKR1C3AKR1C2PTGS1TAS2R14PTGS2 | |
| SCHEMBL8633408 | 0.75 | ALDH1A1 (0.39) | PTGS1PTGS2ALDH1A1 | |
| SCHEMBL8635463 | 0.74 | AKR1C3 (0.45) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL8631102 | 0.73 | AKR1C3 (0.47) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL14176840 | 0.73 | SLC9A1 (0.54) | — | |
| SCHEMBL8634356 | 0.72 | AKR1C3 (0.49) | AKR1C3AKR1C2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381841-B2 | Cardiovascular disorders; antiischemic agenst | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| US-7381841-B2 | Cardiovascular disorders; antiischemic agenst | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| US-7381841-B2 | Cardiovascular disorders; antiischemic agenst | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| WO-2005021492-A1 | PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043401-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043401-A1 | Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | TNNI3, TNNT2, RYR2 | AKR1C3 2866/4885AKR1C2 3538/4885PTGS1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.